Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Bi Pharma Kg.

Christian Kulinna

Peter Sieger

Rolf Banholzer

Helmut Meissner

Andreas Mathes

Peter Specht

Michael Trunk

Werner Rall

Ulrike Werthmann

Manfred Graulich

Rainer Soyka

Juergen Schnaubelt

Peter Seiger

Michael Josef Friedrich Trunk

Manfred Ludwig Graulich

An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.

Process for preparing amino crotonyl compounds

Crystalline monohydrate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions

A method of making a physically stable and homogenous powdered pharmaceutical composition comprising a tiotropium salt and a physiologically acceptable excipient, the method comprising:

Powder formulations containing tiotropium suitable for inhalation

Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-&lsqb;(hydroxydi-2-thienylacetyl)oxy&rsqb;-9,9-dimethyl-3-oxa-9-azoniatricyclo&lsqb;3.3.1.0 &rsqb;nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Growing community of inventors

Attenweiler, Germany

Christian Kulinna